Across TCGA pan-cancer cohorts, LAGE3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LAGE3 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LAGE3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAGE3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where LAGE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.387	0.778	.001	68	view →
LSCC	DFS	Tertile	III,IV	1.000	0.461	.002	24	view →
PDAC	OS	Median	III,IV	0.559	0.311	.025	14	view →
LUAD	OS	Median	II,III,IV	0.893	0.453	.026	6	view →
CCRCC	OS	Tertile	All	1.000	0.733	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LAGE3 tumor-vs-normal RNA expression · all LAGE3 data types